Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 34

1.

Study of Sex Differences in Duloxetine Efficacy for Depression in Transgenic Mouse Models.

Xu Y, Ma L, Jiang W, Li Y, Wang G, Li R.

Front Cell Neurosci. 2017 Oct 31;11:344. doi: 10.3389/fncel.2017.00344. eCollection 2017.

2.

Antidepressant-induced Dopamine Receptor Dysregulation: A Valid Animal Model of Manic-Depressive Illness.

Demontis F, Serra F, Serra G.

Curr Neuropharmacol. 2017 Apr;15(3):417-423. doi: 10.2174/1570159X14666160715165648. Review.

3.

Serotonin receptors in depression: from A to B.

Nautiyal KM, Hen R.

F1000Res. 2017 Feb 9;6:123. doi: 10.12688/f1000research.9736.1. eCollection 2017. Review.

4.

Anti-anhedonic effect of selective serotonin reuptake inhibitors with affinity for sigma-1 receptors in picrotoxin-treated mice.

Hasebe S, Ago Y, Watabe Y, Oka S, Hiramatsu N, Tanaka T, Umehara C, Hashimoto H, Takuma K, Matsuda T.

Br J Pharmacol. 2017 Feb;174(4):314-327. doi: 10.1111/bph.13692. Epub 2017 Jan 26.

5.

Role of Reward Sensitivity and Processing in Major Depressive and Bipolar Spectrum Disorders.

Alloy LB, Olino T, Freed RD, Nusslock R.

Behav Ther. 2016 Sep;47(5):600-621. doi: 10.1016/j.beth.2016.02.014. Epub 2016 Mar 7.

6.
7.

Incongruent reduction of dopamine transporter availability in different subgroups of alcohol dependence.

Yen CH, Shih MC, Cheng CY, Ma KH, Lu RB, Huang SY.

Medicine (Baltimore). 2016 Aug;95(33):e4048. doi: 10.1097/MD.0000000000004048.

8.

Failure of memantine to "reverse" quinpirole-induced hypomotility.

Demontis F, Serra G.

World J Psychiatry. 2016 Jun 22;6(2):215-20. doi: 10.5498/wjp.v6.i2.215. eCollection 2016 Jun 22.

9.

Essential Role of Mesolimbic Brain-Derived Neurotrophic Factor in Chronic Social Stress-Induced Depressive Behaviors.

Wook Koo J, Labonté B, Engmann O, Calipari ES, Juarez B, Lorsch Z, Walsh JJ, Friedman AK, Yorgason JT, Han MH, Nestler EJ.

Biol Psychiatry. 2016 Sep 15;80(6):469-478. doi: 10.1016/j.biopsych.2015.12.009. Epub 2015 Dec 15.

10.

Obesity and Its Potential Effects on Antidepressant Treatment Outcomes in Patients with Depressive Disorders: A Literature Review.

Woo YS, Seo HJ, McIntyre RS, Bahk WM.

Int J Mol Sci. 2016 Jan 12;17(1). pii: E80. doi: 10.3390/ijms17010080. Review.

11.

Triple reuptake inhibitors as potential next-generation antidepressants: a new hope?

Sharma H, Santra S, Dutta A.

Future Med Chem. 2015;7(17):2385-406. doi: 10.4155/fmc.15.134. Epub 2015 Nov 30. Review.

12.

Involvement of adrenoceptors, dopamine receptors and AMPA receptors in antidepressant-like action of 7-O-ethylfangchinoline in mice.

Sheng ZF, Cui XY, Cui SY, Yu B, Zhang XQ, Li SJ, Cao Q, Huang YL, Xu YP, Song JZ, Ding H, Lin ZG, Yang G, Zhang YH.

Acta Pharmacol Sin. 2015 Aug;36(8):949-56. doi: 10.1038/aps.2015.57.

13.

Memantine: New prospective in bipolar disorder treatment.

Serra G, Demontis F, Serra F, De Chiara L, Spoto A, Girardi P, Vidotto G, Serra G.

World J Psychiatry. 2014 Dec 22;4(4):80-90. doi: 10.5498/wjp.v4.i4.80. Review.

14.

Antidepressant-like effect of Hoodia gordonii in a forced swimming test in mice: evidence for involvement of the monoaminergic system.

Citó MC, Silva MI, Santos LK, Fernandes ML, Melo FH, Aguiar JA, Lopes IS, Sousa PB, Vasconcelos SM, Macêdo DS, Sousa FC.

Braz J Med Biol Res. 2015 Jan;48(1):57-64. Epub 2014 Nov 7.

15.

Design and synthesis of 4-heteroaryl 1,2,3,4-tetrahydroisoquinolines as triple reuptake inhibitors.

Liu S, Zha C, Nacro K, Hu M, Cui W, Yang YL, Bhatt U, Sambandam A, Isherwood M, Yet L, Herr MT, Ebeltoft S, Hassler C, Fleming L, Pechulis AD, Payen-Fornicola A, Holman N, Milanowski D, Cotterill I, Mozhaev V, Khmelnitsky Y, Guzzo PR, Sargent BJ, Molino BF, Olson R, King D, Lelas S, Li YW, Johnson K, Molski T, Orie A, Ng A, Haskell R, Clarke W, Bertekap R, O'Connell J, Lodge N, Sinz M, Adams S, Zaczek R, Macor JE.

ACS Med Chem Lett. 2014 May 13;5(7):760-5. doi: 10.1021/ml500053b. eCollection 2014 Jul 10.

16.

Dopamine genetic risk score predicts depressive symptoms in healthy adults and adults with depression.

Pearson-Fuhrhop KM, Dunn EC, Mortero S, Devan WJ, Falcone GJ, Lee P, Holmes AJ, Hollinshead MO, Roffman JL, Smoller JW, Rosand J, Cramer SC.

PLoS One. 2014 May 16;9(5):e93772. doi: 10.1371/journal.pone.0093772. eCollection 2014.

17.

Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.

Sharma H, Santra S, Debnath J, Antonio T, Reith M, Dutta A.

Bioorg Med Chem. 2014 Jan 1;22(1):311-24. doi: 10.1016/j.bmc.2013.11.017. Epub 2013 Nov 19.

18.

Mapping anhedonia onto reinforcement learning: a behavioural meta-analysis.

Huys QJ, Pizzagalli DA, Bogdan R, Dayan P.

Biol Mood Anxiety Disord. 2013 Jun 19;3(1):12. doi: 10.1186/2045-5380-3-12.

19.

Comparison of psychological symptoms and serum levels of neurotransmitters in Shanghai adolescents with and without internet addiction disorder: a case-control study.

Zhang HX, Jiang WQ, Lin ZG, Du YS, Vance A.

PLoS One. 2013 May 3;8(5):e63089. doi: 10.1371/journal.pone.0063089. Print 2013.

20.

Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.

Santra S, Gogoi S, Gopishetty B, Antonio T, Zhen J, Reith ME, Dutta AK.

ChemMedChem. 2012 Dec;7(12):2093-100. doi: 10.1002/cmdc.201200352. Epub 2012 Oct 11.

Supplemental Content

Support Center